ライフサイエンスコーパス: post-transplantation

1 viral, blood group or third party antibodies post transplantation.

2 both the adaptive and innate immune systems post transplantation.

3 ravenous enzyme replacement therapy (IV-ERT) post transplantation.

4 nts with stable function between 3-24 months post transplantation.

5 rgen-specific IgE or IgG responses 24 months post-transplantation.

6 served after a median follow-up of 5.5 years post-transplantation.

7 tulates pulmonary IRI that occurs clinically post-transplantation.

8 ectomy of the remaining native kidney at d 5 post-transplantation.

9 formed prior to transplantation and one-year post-transplantation.

10 a median time of 77 months to graft failure post-transplantation.

11 obtained at baseline and 3, 6, and 12 months post-transplantation.

12 icrobiota composition pretransplantation and post-transplantation.

13 s, and complete drug withdrawal by 24 months post-transplantation.

14 cell subset was depleted at all time-points post-transplantation.

15 profiles were interrogated at 2- and 4-weeks post-transplantation.

16 ial or surgical biopsies and 6 at autopsy or post-transplantation.

17 hort of 172 serum samples collected serially post-transplantation.

18 with stable function between 3 and 24 months post-transplantation.

19 T, with 90 in complete remission at 3 months post-transplantation.

20 ncreased hemodynamic performance at 20 weeks post-transplantation.

21 ing and volume gain at baseline and 6 months post-transplantation.

22 ificant retention in mouse livers at 8 weeks post-transplantation.

23 versal of neurological disability at 3 years post-transplantation.

24 and at specified intervals through 12 months post-transplantation.

25 ity as a critical property for MDSC survival post-transplantation.

26 enhance Treg-dependent functions, including post-transplantation.

27 als were sacrificed at 24 h, 72 h and 1 week post-transplantation.

28 d to display a compromised BBB up to 11 days post-transplantation.

29 an grafts formed tumors approximately 1 year post-transplantation.

30 up in regard to persistent albumin secretion post-transplantation.

31 resulted in higher human C-peptide levels in post-transplantation.

32 ore slowly than the normal marrow at 4 weeks post-transplantation.

33 mRNAs, which reached maximal levels 3 to 6 h post-transplantation.

34 ry T cell phenotype in the allograft 30 days post-transplantation.

35 n, pre-induction disease stage, and response post-transplantation.

36 incidence of grade 2-4 acute GVHD at day 100 post-transplantation.

37 ctable levels of gene correction 16-19 weeks post-transplantation.

38 that donor macrophages can persist for years post-transplantation.

39 ted with significant mortality and morbidity post-transplantation.

40 r endothelium injury during preservation and post-transplantation.

41 sting pre-transplant, expansion and infusion post-transplantation.

42 -specific, antibody-positive ABMR >=365 days post-transplantation.

43 henocopied Id cDKO cardiac fibrosis 4 months post-transplantation.

44 could shape the nature of the host response post-transplantation.

45 in the patient who came to autopsy 16 years post-transplantation.

46 e who came to autopsy 18 months and 16 years post-transplantation.

47 The patient was discharged on day 18 post-transplantation.

48 lovirus monitoring by PCR through to day 100 post-transplantation.

49 e HLA-A, B, DR matching, donor age, and time post-transplantation.

50 .6% vs. 71.5 +/- 1.8%; P = 0.065) at 30 days post-transplantation.

51 Patients were followed for >/=7 years post-transplantation.

52 test transplant recipients for alloantibody post-transplantation?

53 One-year post-transplantation, 29/823 (3.5%) of seropositive SOT

54 ecovered significant cognitive function from post-transplantation (80 days) to 5 years in all tests (

55 Post-transplantation, a combination of granulocyte colon

56 thresholds with overall mortality by 1 year post-transplantation, adjusting for the use of pre-empti

57 or bronchial hypoxia as a driving factor for post-transplantation airway complications.

58 entified renal miR-182 as the main driver of post-transplantation AKI.

59 0.63, p < 0.0001; CPV: r = 0.43, p = 0.004) post-transplantation along with AT(2)R mRNA in the donor

60 increase significantly at early time points post-transplantation and are detectable by PCR analysis

61 eduction was particularly apparent at 4 week post-transplantation and is independent of CsA immunosup

62 as measured to evaluate human islet function post-transplantation and prior to microPET imaging.

63 experienced disease progression at 115 days post-transplantation and responded to donor lymphocyte i

64 fit was calculated as the difference between post-transplantation and waitlist life expectancy.

65 ncided with post-ischemic injury over 2 days post-transplantation and was localized by in situ hybrid

66 imerism (median time of first dose, 9 months post-transplantation) and to 24 patients for relapse.

67 diagnosed with CLAD at a median of 95 weeks post-transplantation, and 79 (32%) had 114 episodes of R

68 domonas aeruginosa, are generally manageable post-transplantation, and are associated with favourable

69 ve advanced leukemia, receive growth factors post-transplantation, and have undergone transplantation

70 detect AR in blood independent of age, time post-transplantation, and sample source without addition

71 patients, who came to autopsy 9 and 12 years post-transplantation, and two patients with Parkinson's

72 the severity of hepatitis C virus recurrence post-transplantation are discussed.

73 of autologous anti-multiple myeloma immunity post-transplantation are modalities being tested to enha

74 in adult SOT recipients before and one-year post-transplantation as well as evidence of MMRV infecti

75 at day +7 (P = .01) and day +14 (P = .00003) post-transplantation as well as with the allograft CD34(

76 At 35-47 d post-transplantation, astrocytes appeared morphologicall

77 Five patients (12%) remain alive post-transplantation at >or= 63, >or= 71, >or= 86, >or=

78 Transplanted lungs were evaluated at 6 d post-transplantation based on pulmonary function, histol

79 ength of purifying selection acting in early post-transplantation bone marrow.

80 nts and at 6, 12 and 24 months in recipients post-transplantation by allergen microarray.

81 can contribute to biliary remodeling (e.g., post-transplantation) by functional deregulation of the

82 tigated the effect of an early (mo 3 to mo 6 post transplantation) C/D ratio below 1.05.

83 significant therapeutic potential to prevent post-transplantation cancer in immunosuppressed patients

84 component in the progression of CsA-induced post-transplantation cancer.

85 ces were seen between HTK and control hearts post-transplantation (cardiac index: control 49.5+/-6% a

86 The patients received the usual post-transplantation care given at the institution.

87 Post-transplantation, CD146(+) and CD166(+) progenitors

88 ersus-host disease (GVHD), which is the main post-transplantation challenge when HLA-matched donors a

89 Pretransplantation and post-transplantation clinical variables and data from a

90 AT(2)R mRNA in the donor hearts at one-year post-transplantation (CMIT: r = 0.3, p < 0.0001; CPV: r

91 Key efficacy end points were post-transplantation complete plus near-complete respons

92 oliferative disorder (PTLD) is a devastating post-transplantation complication often associated with

93 A post-transplantation conditioning regimen of total lymph

94 al implications, the effect of DCD livers on post-transplantation costs has not been studied.

95 Furthermore, DCD post-transplantation costs were 30% higher than DBD cost

96 One-year, post-transplantation costs were higher for DCD recipient

97 We sought to compare the post-transplantation course of patients with AATD and AA

98 Post-transplantation CR+nCR rate was significantly highe

99 es to tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide (cyclophosphamide

100 ietic cell transplantation (Haplo-HCT) using post-transplantation cyclophosphamide (PT-Cy) is increas

101 t disease (GVHD) prophylaxis with high-dose, post-transplantation cyclophosphamide (PTCy) have been d

102 Post-transplantation cyclophosphamide (PTCy) recently ha

103 on performed using T-cell-replete grafts and post-transplantation cyclophosphamide achieves outcomes

104 om two randomized trials have suggested that post-transplantation cyclophosphamide can reduce the ris

105 cal related bone marrow transplantation with post-transplantation cyclophosphamide expanded the donor

106 imens using either maraviroc, bortezomib, or post-transplantation cyclophosphamide for GvHD prophylax

107 NMA haplo-BMT with post-transplantation cyclophosphamide has encouraging sa

108 lete grafts from haploidentical donors using post-transplantation cyclophosphamide may represent a so

109 transplantation conditioning and high dose, post-transplantation cyclophosphamide to prevent graft r

110 Tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide was the most promi

111 ) for tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide, 0.98 (0.76-1.27;

112 l equivalent) starting on day -3 (except the post-transplantation cyclophosphamide, as indicated), wi

113 Conclusion Post-transplantation cyclophosphamide-based HAPLO transp

114 patients with Hodgkin lymphoma who received post-transplantation cyclophosphamide-based haploidentic

115 NMA, T-cell-replete haplo-BMT with high-dose post-transplantation cyclophosphamide.

116 loidentical bone marrow transplantation with post-transplantation cyclophosphamide.

117 ] for tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide; 73 [82%] for tacr

118 92 to tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide; and six were excl

119 with tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide; ten (11%) had gra

120 50 perfusion units) at a much earlier period post-transplantation (day 4) compared to animals that re

121 axis was solely with PTCy at 50 mg/kg/day on post-transplantation days +3 and +4.

122 iated with increased risk of early (day 0-60 post-transplantation) death (adjusted hazard ratio [HR]

123 ess than 6.5 ng/mL during the first 2 months post-transplantation demonstrated a significantly higher

124 He was vaccinated 4 years post-transplantation, despite diagnosis of a new low-gra

125 ntervention resulted in reduced incidence of post transplantation diabetes (7.6% versus 15.6% respect

126 ers of patients entered on the waiting list, post-transplantation, died waiting, and currently waitin

127 ion R did not affect stem-cell mobilization, post-transplantation early complications, duration of ho

128 ovirus (CMV) continues to be a major problem post-transplantation; early markers for predicting patie

129 Direct imaging of post-transplantation endothelial cells is only possible

130 remissions for the majority of patients with post-transplantation Epstein-Barr virus-related lymphoma

131 antation, this decreased markedly by 4 weeks post-transplantation even in the absence of CsA immunosu

132 However, it is not known how specific post-transplantation events (acute or chronic graft-vers

133 amine the relationship between ethnicity and post-transplantation events and determine their net effe

134 Our model demonstrates that common post-transplantation events drive movement from one post

135 splantation quantitative thallium uptake and post-transplantation extent and the histological distrib

136 Pre- and post-transplantation factors can assist in identifying p

137 tween January 2005 and December 2009 and had post-transplantation FDG positron emission tomography/co

138 who received a transplant survive (75%) with post-transplantation follow-up as long as 13 years.

139 psies obtained during the first three months post-transplantation from 172 patients (median follow-up

140 oinfection and the severity of liver disease post-transplantation, graft, or patient survival.

141 c fibrosis-related arthropathy increased the post-transplantation hazard of death.

142 ined with ribavirin for 24 weeks in treating post-transplantation HCV infection.

143 well-tolerated interferon-free treatment for post-transplantation HCV infection.

144 After 7 to 65 days post-transplantation, hearts were harvested and processe

145 A rise in post-transplantation hemoglobin was a significant factor

146 onsumption of camel-derived food products to post-transplantation hepatitis E, which, if detected at

147 ene silencing techniques in the treatment of post-transplantation host rejection is not long lasting

148 By 3 days post-transplantation, however, there were no longer any

149 At 10 days post-transplantation, hUC-MSC sheets remain on ectopic t

150 context of suppressed cell-mediated immunity post-transplantation, humoral immunity has a role in red

151 Obesity was a risk factor for post-transplantation hypertension, dyslipidemia, and dia

152 g of 377 microRNAs in the first urine passed post-transplantation identified 6 microRNAs, confirmed t

153 BM-derived Tns and pDCs favorably regulated post-transplantation immunity in allogeneic hematopoieti

154 donor kidney transplantation in addition to post-transplantation immunosuppression.

155 of rapamycin (mTOR) inhibitor rapamycin as a post-transplantation immunosuppressive significantly red

156 Six patients received post-transplantation immunosuppressive therapy with meth

157 , sampled at varying times in the first week post-transplantation in a separate transplant center.

158 27(-) B cells were increased through 5 years post-transplantation in both tolerant and nontolerant re

159 , survival, and differentiationin vitro, and post-transplantation in vivo.

160 pe could serve as a new biomarker to predict post-transplantation infection and to stratify patients

161 Post-transplantation infection causes high mortality and

162 .5 years; 67% male; at a median of 2.0 years post-transplantation, (interquartile range 1.3-3.3 years

163 e intervention to improve glucose metabolism post transplantation is unproven.

164 Administration of LEN post-transplantation is associated with excessive rates

165 The MTD of post-transplantation LEN, in combination with AZA, was d

166 lated as the difference between waitlist and post-transplantation life expectancy.

167 ber of diseases including liver ischemia and post-transplantation liver failure.

168 PURPOSE Adult post-transplantation lymphoproliferative disease (PTLD)

169 Epstein-Barr virus (EBV)-associated post-transplantation lymphoproliferative disease (PTLD)

170 Post-transplantation lymphoproliferative disease (PTLD)

171 vere life-threatening infections and trigger post-transplantation lymphoproliferative disease (PTLD).

172 ugh TRAFs in tumor tissue from patients with post-transplantation lymphoproliferative disease and non

173 Tumors from six of the patients with post-transplantation lymphoproliferative disease were po

174 Tumors from eight patients with post-transplantation lymphoproliferative disease, two pa

175 Post-transplantation lymphoproliferative disorder (PTLD)

176 ce, risk factors, treatment, and outcomes of post-transplantation lymphoproliferative disorder (PTLD)

177 Post-transplantation lymphoproliferative disorder (PTLD)

178 To further elucidate the role of del-LMP1 in post-transplantation lymphoproliferative disorders (PT-L

179 actors for overall survival in patients with post-transplantation lymphoproliferative disorders (PTLD

180 xcluding non-melanoma skin cancers [NMSCs]), post-transplantation lymphoproliferative disorders (PTLD

181 Post-transplantation management was provided in accordan

182 transgene expression between 14 and 28 days post-transplantation, many of these changes began to nor

183 Post-transplantation mean left ventricular ejection frac

184 At six months post-transplantation, mean serum creatinine was 2.0 +/-

185 Remarkably, 9 days post-transplantation, mice receiving scWAT from exercise

186 eadout, enables-via simple visualization-the post-transplantation monitoring of common opportunistic

187 jection, and should facilitate point-of-care post-transplantation monitoring.

188 </= 44.0 mm Hg had significant increases in post-transplantation mortality (hazard ratio = 1.58; 95%

189 improved, with a dramatic reduction in early post-transplantation mortality and excellent 5-year surv

190 The 30-day post-transplantation mortality rate was 67% for patients

191 Models of 90-day and 1-year post-transplantation mortality were developed using reci

192 els provide a means of assessing the risk of post-transplantation mortality, giving clinicians import

193 exception points) due to their high pre- and post-transplantation mortality.

194 </= 44.0 mm Hg was associated with increased post-transplantation mortality.

195 plantation are also at higher risk for early post-transplantation mortality.

196 ith hepatocellular carcinoma poorly estimate post-transplantation mortality.

197 ncreasing age was associated with increasing post-transplantation mortality.

198 reservation solution demonstrated comparable post-transplantation myocardial function to standard con

199 itopes in Goodpasture's disease and Alport's post-transplantation nephritis with the intention of fin

200 In contrast, in patients with Alport's post-transplantation nephritis, alloantibodies bound to

201 Alport's post-transplantation nephritis, which is mediated by all

202 sture's disease and 2 patients with Alport's post-transplantation nephritis.

203 Moreover, post-transplantation non-cell-autonomous mechanisms rest

204 pients and the effect of age on waitlist and post-transplantation outcomes and on transplant-related

205 This study sought to investigate post-transplantation outcomes as a function of race and

206 Advances in biomaterials can improve pre-/post-transplantation outcomes by integrating biophysioch

207 effects of room-air oxygenation on pre- and post-transplantation outcomes of patients with HPS.

208 rushed transplantation to achieve desirable post-transplantation outcomes.

209 ants are known to be associated with adverse post-transplantation outcomes.

210 pse free but full donor chimeras at 9 months post-transplantation (P = .0071).

211 in group 2 at 1 year (91%), and 5 year (87%) post-transplantation (P = 0.0019).

212 Cohort B included post-transplantation patients who had either no cirrhosi

213 safe and effective for the growing number of post-transplantation patients who may be candidates for

214 The nephrotic syndrome in early post-transplantation period should prompt a work-up for

215 treated animals was reduced in the immediate post-transplantation period, but by day 100 was increase

216 result in beta cell destruction in the early post-transplantation period.

217 within the graft and persist throughout the post-transplantation period.

218 (56 v 50 years; P < .001), and had delays in post-transplantation platelets recovery (39 v 27 days; P

219 less prevalent and/or less severe within the post-transplantation population, which may suggest attri

220 eceptors from perioperation through one-year post-transplantation predict the transplant coronary art

221 s indicate that OECs survive longer than FBs post-transplantation, preserve axons and neurons, and re

222 Post-transplantation progression of neurologic dysfuncti

223 phocytes and in the donor hearts at one-year post-transplantation proved to be multivariate predictor

224 with several aspects of modern management of post-transplantation PTLD.

225 ion do not meet criteria for a more specific post-transplantation pulmonary syndrome.

226 Numerous idiopathic post-transplantation pulmonary syndromes have been descr

227 with aspartate aminotransferase (AST) 14-day post-transplantation (q < 0.05) and were more abundant i

228 Two years post-transplantation, recipients' allergen-specific IgE

229 f grafted NPCs were found to survive at 24 h post-transplantation, regardless of injury status of the

230 udy indicated the potential superiority of a post-transplantation regimen of cyclophosphamide, tacrol

231 come is largely due to a higher incidence of post-transplantation relapse (20% to 30%).

232 tiple costimulatory ligands on AML blasts at post-transplantation relapse (PD-L1, B7-H3, CD80, PVRL2)

233 tivity of combined LEN/AZA administration in post-transplantation relapse.

234 ied a transcriptional signature specific for post-transplantation relapses and highly enriched in imm

235 immunotherapy can cure blood cancers: still, post-transplantation relapses remain frequent.

236 re collected from eight patients with severe post-transplantation reperfusion edema.

237 ftment is assessed 4-6 weeks and 10-12 weeks post-transplantation, respectively, with preparation and

238 er doses of opioid medications were the only post-transplantation risk factor for delirium onset (haz

239 t and prior pain, and higher BUN levels were post-transplantation risk factors for greater delirium s

240 dds of neutropenia after the first or second post-transplantation rituximab increased three-fold with

241 wever, neutropenia after the first or second post-transplantation rituximab treatment occurred in 52%

242 h B-cell non-Hodgkin's lymphoma who received post-transplantation rituximab.

243 genotype other than 1a, and 5 persons had no post-transplantation serum specimens available.

244 Post-transplantation serum specimens were unavailable fo

245 nly used to guide pre-emptive therapy in the post-transplantation setting, few data are available cor

246 Analysis at 75 d post-transplantation showed 2 of the 6 clones engrafting

247 on of liver sections of mice up to 16 months post-transplantation showed no evidence of liver damage.

248 ansplantation events drive movement from one post-transplantation state to another and influence outc

249 Six months post-transplantation, subjects without de novo donor-spe

250 three periods: survival to transplantation, post-transplantation survival and overall survival (i.e.

251 it substantially because age diminishes both post-transplantation survival and waitlist survival appr

252 acteria, especially Mycobacterium abscessus, post-transplantation survival has not been definitively

253 Post-transplantation survival improved annually.

254 Post-transplantation survival in AL has improved, with a

255 might enable clinicians to accurately assess post-transplantation survival in patients with hepatocel

256 Identifying characteristics that affect post-transplantation survival may improve patient select

257 We modeled the post-transplantation survival of adult, first-time liver

258 (88.4%), 3-year (80.3%), and 5-year (74.0%) post-transplantation survival of all other transplant re

259 The post-transplantation survival of patients with hemochrom

260 During 1990-1996, the post-transplantation survival of patients with hemochrom

261 We identified thresholds associated with post-transplantation survival using cubic spline analysi

262 sk of disease relapse and the probability of post-transplantation survival versus IPSS-R (concordance

263 Post-transplantation survival was 95 +/- 4% at three yea

264 Rates of 3-year unadjusted post-transplantation survival were 84% for patients with

265 xamined the consequences of donor smoking on post-transplantation survival, and the potential effect

266 (86.1%), 3-year (80.8%), and 5-year (77.3%) post-transplantation survival, which was not different f

267 ransplantation mortality and similar rate of post-transplantation survival.

268 ncreased waiting-list survival but decreased post-transplantation survival.

269 that patients with hemochromatosis have poor post-transplantation survival.

270 other causes of liver disease with regard to post-transplantation survival.

271 t affect waiting-list survival but decreased post-transplantation survival.

272 ppraise carefully the high risk of decreased post-transplantation survival.

273 models to identify variables that influence post-transplantation survival.

274 d Cox proportional hazards analysis to model post-transplantation survival.

275 chronic lung allograft dysfunction and worse post-transplantation survival.

276 tation, at least in the acute phase (12 days post-transplantation), surviving xenografts were detecte

277 ciated with worse patient and graft survival post-transplantation than other liver diseases.

278 At 4 weeks post transplantation, the engrafted cells were found to

279 At 20 weeks post transplantation, the maturing engrafted cells were

280 By 6 months post-transplantation, the reconstituted mice had develop

281 reactive astrocytes and microglia at 1 week post-transplantation, this decreased markedly by 4 weeks

282 f immunosuppressive drugs are routinely used post-transplantation to prevent rejection and/or other c

283 iac neural tube and neural crest at 12 hours post-transplantation to the midbrain, but was subsequent

284 CsA-induced VEGF overexpression in terms of post-transplantation tumor development, we injected CT26

285 By integrating pre- and post-transplantation (Tx) mixed lymphocyte reaction-dete

286 thful recapitulation of tissue-specific fate post-transplantation underscores the functional potentia

287 to transplantation, and have no prospect for post-transplantation use.

288 f HLA matching, and cold-ischemia time), and post-transplantation variables (presence or absence of a

289 If post-transplantation variables that were highly correlat

290 and reached a clinically relevant difference post-transplantation versus baseline.

291 Of these 43 patients, 30 (70%) had a post-transplantation virologic response at 12 weeks, 10

292 ts given sofosbuvir and ribavirin, 49% had a post-transplantation virologic response.

293 At 20 days post-transplantation, W nCuO-exposed plants had ~56% low

294 Increased mortality at 3-months post-transplantation was associated with acute liver fai

295 During immune reconstitution post-transplantation we observed significant though tran

296 al to transplantation, and survival one year post-transplantation were similar to patients without se

297 sed 6-fold in xenograft recipients at day 21 post-transplantation when compared with naive animals.

298 ed near complete BBB reconstitution at day 5 post-transplantation, whereas animals that received sali

299 graft dysfunction grade 3 (PGD3) within 72 h post-transplantation, with a prespecified objective perf

300 Among patients who survived the first post-transplantation year, biventricular CHD patients ex